Jeppe Zacho
Novo Nordisk
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jeppe Zacho.
Diabetes, Obesity and Metabolism | 2018
Yutaka Seino; Yasuo Terauchi; Takeshi Osonoi; Daisuke Yabe; Nobuyuki Abe; Tomoyuki Nishida; Jeppe Zacho; Shizuka Kaneko
To assess the safety and efficacy of monotherapy with once‐weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes (T2D).
Diabetes, Obesity and Metabolism | 2018
Kohei Kaku; Yuichiro Yamada; Hirotaka Watada; Atsuko Abiko; Tomoyuki Nishida; Jeppe Zacho; Arihiro Kiyosue
To evaluate the safety and efficacy of once‐weekly subcutaneous semaglutide as monotherapy or combined with an oral antidiabetic drug (OAD) vs an additional OAD added to background therapy in Japanese people with type 2 diabetes (T2D) inadequately controlled on diet/exercise or OAD monotherapy.
Diabetes, Obesity and Metabolism | 2016
Helena W. Rodbard; Bertrand Cariou; Thomas R. Pieber; Lars Endahl; Jeppe Zacho; J. G. Cooper
To evaluate the efficacy and safety of two insulin intensification strategies for patients with type 2 diabetes previously treated with basal insulin – insulin degludec (IDeg) and insulin aspart (IAsp) – administered as a co‐formulation (IDegAsp) or as a basal‐bolus regimen (IDeg and IAsp in separate injections).
Diabetes, Obesity and Metabolism | 2016
Vanita R. Aroda; Timothy S. Bailey; Bertrand Cariou; S. Kumar; Lawrence A. Leiter; Philip Raskin; Jeppe Zacho; Thomas H. Andersen; Athena Philis-Tsimikas
To evaluate the efficacy and safety of adding insulin degludec (IDeg) to treatment in patients with type 2 diabetes receiving liraglutide and metformin and qualifying for treatment intensification because of inadequate glycaemic control.
Diabetes Care | 2018
Ildiko Lingvay; Cyrus V. Desouza; Katarina Lalic; Ludger Rose; Thomas Kruse Hansen; Jeppe Zacho; Thomas R. Pieber
OBJECTIVE To investigate the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This 26-week, multicenter, double-blind trial involved patients diagnosed with type 2 diabetes with HbA1c 7.0–10.0% (53–86 mmol/mol) and treated with diet and exercise with or without metformin. Patients were randomized 2:2:1 to once-daily semaglutide, liraglutide, or placebo in one of four volume-matched doses (semaglutide 0.05, 0.1, 0.2, or 0.3 mg and liraglutide 0.3, 0.6, 1.2, or 1.8 mg, with both compared within each volume-matched dose group). Primary end point was change in HbA1c from baseline to week 26. RESULTS In total, 705 randomized patients were exposed to trial products. At week 26, a dose-dependent change in HbA1c was observed with semaglutide from −1.1% (0.05 mg) to −1.9% (0.3 mg) and with liraglutide from −0.5% (0.3 mg) to −1.3% (1.8 mg) (all P < 0.001 in favor of volume-matched semaglutide dose). Change with pooled placebo was −0.02% (P < 0.0001 vs. semaglutide). Gastrointestinal (GI) disorders were the most common adverse events (AEs) with semaglutide and liraglutide, occurring in 32.8–54.0% and 21.9–41.5% of patients, respectively. CONCLUSIONS Once-daily semaglutide at doses up to 0.3 mg/day resulted in greater reductions in HbA1c compared with liraglutide or placebo but with a higher frequency of GI AEs.
Diabetes, Obesity and Metabolism | 2018
K.C.C. Petri; Steen H. Ingwersen; Anne Flint; Jeppe Zacho; Rune Viig Overgaard
To evaluate dose levels for semaglutide, a glucagon‐like peptide‐1 analogue approved for the treatment of type 2 diabetes, by examining the effects of demographic factors on efficacy and safety in an exposure‐response analysis.
Journal of Diabetes Investigation | 2017
Yukiko Onishi; Kenichi Yamada; Jeppe Zacho; Jan Ekelund; Yasuhiko Iwamoto
Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and insulin aspart (30%). The present exploratory trial investigated the safety of switching unit‐to‐unit from twice‐daily basal or pre‐mix insulin to twice‐daily IDegAsp in Japanese patients with type 2 diabetes.
Diabetes, Obesity and Metabolism | 2018
J. Hans DeVries; Cyrus V. Desouza; Srikanth Bellary; Jeffrey Unger; Oluf K. H. Hansen; Jeppe Zacho; Vincent Woo
To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects.
Diabetes Therapy | 2018
K.C.C. Petri; Steen H. Ingwersen; Anne Flint; Jeppe Zacho; Rune Viig Overgaard
Advances in Therapy | 2018
Ippei Ikushima; Lene Jensen; Anne Flint; Tomoyuki Nishida; Jeppe Zacho; Shin Irie